Thank you for contributing to Archives of Plastic Surgery. Please read the instructions carefully and observe all the directions given. Failure to do so may result in unnecessary delays in publishing your article.

SUBMISSION CHECKLIST
All manuscripts must be submitted at the following link:
https://mc.manuscriptcentral.com/archplastsurg

☐ AUTHOR INFORMATION
- All authors: full name, academic degree(s), departmental and institutional affiliation(s)
- Corresponding author: full name, academic degree(s), department, affiliation, mailing address, telephone and fax number, e-mail address
- Conflict of interest statement in respect to all authors

☐ MANUSCRIPT FILE
- Must be digital - hard copy submissions are not accepted. See the section Article Types for word limit and main text structure

☐ ABSTRACT AND KEYWORDS
- See the section Article Types for word limit and abstract structure

☐ REFERENCES
- Cited sequentially in AMA style

☐ TABLES & FIGURES
- Cited sequentially in the main document
- Tables must be included in the main document file and Table captions should appear above every table
- Must be saved separately from the main document
- The main document should have a “Figure Captions” section (if figures are used)

☐ VIDEOS
- Cited sequentially in the main document, must be saved separately from the main document
- The main document should have a “Video Captions” section (if videos are used)

☐ PERMISSIONS
- Required if you plan to reproduce content from a published source or include a photograph of a patient
- Patient permission forms available at www.thieme.com/journal-authors
ABOUT ARCHIVES OF PLASTIC SURGERY

Archives of Plastic Surgery (Arch Plast Surg, APS) is the official journal of the Korean Society of Plastic and Reconstructive Surgeons, Hong Kong Society of Plastic and Reconstructive and Aesthetic Surgeons, Indonesian Association of Plastic Reconstructive and Aesthetic Surgeons, Singapore Association of Plastic Surgeons, The Society of Plastic and Reconstructive Surgeons of Thailand. Manuscripts on any aspect of plastic surgery–original clinical or laboratory research, operative procedures, comprehensive reviews–as well as selected ideas and innovations, letters, case reports, and correspondence are invited for publication. This journal will be published bimonthly.

Manuscripts for submission to APS should be prepared according to the following instructions. APS follow the guidelines and best practices published by professional organizations, including Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals from ICMJE and Principles of Transparency and Best Practice in Scholarly Publishing (joint statement by COPE, DOAJ, WAME, and OASPA)

Any physician or researcher throughout the world can submit a manuscript if the scope of the manuscript is appropriate. Only those manuscripts that are original, have not been published elsewhere, and are not currently being considered for inclusion in another publication will be considered for publication in APS.

SUBMISSION OF MANUSCRIPTS

All manuscripts should be submitted online via the journal's website https://mc.manuscriptcentral.com/archplastsurg by the corresponding author. Submission instructions are available on the website. All articles submitted to the journal must comply with these instructions. Failure to do so will result in return of the manuscript and possible delay in publication. Send all correspondence regarding submitted manuscripts to:

Joon Pio Hong, MD, PhD, MMM
Editor-in-Chief
Archives of Plastic Surgery
Address: 101-2003, Lotte Castle President, 109, Mapodaero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-3472-8252, Fax: +82-2-3472-4254
E-mail: apsedit@gmail.com

RESEARCH AND PUBLICATION ETHICS

The Journal adheres to the guidelines and best practices published by professional organizations, including Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals from ICMJE and Principles of Transparency and Best Practice in Scholarly Publishing (joint statement by COPE, DOAJ, WAME, and OASPA)

Registration of Clinical Trial Research

It is recommended that any research that deals with a clinical trial be registered with a primary national clinical trial registration site, such as http://cris.cdc.go.kr/, or other sites accredited by the WHO as listed at http://www.who.int/ictrp/en/.

Conflict of Interest Statement

The corresponding author must inform the editor of any potential conflicts of interest that could influence the authors' interpretation of the data. Examples of potential conflicts of interest are financial support from or connections to pharmaceutical companies, political pressure from interest groups, and academically related issues. In particular, all sources of funding applicable to the study should be explicitly stated.
**Statement of Informed Consent**

Copies of written informed consent and institutional review board (IRB) approval for clinical research should be kept. If necessary, the editor or reviewers may request copies of these documents to resolve questions about IRB approval and study conduct. In addition, for studies conducted with human subjects, the method by which informed consent was obtained from the participants (i.e., verbal or written) also needs to be stated in the Methods section. For research with animal subjects, studies should be approved by an Institutional Animal Care and Use Committee (IACUC).

**Patient Photographic and Videographic Consent**

Patients introduced in the manuscripts should be informed and aware that their photographs, videotapes, and other images (imaging records) will be released by the authors, and the authors should attach the Authorization and Release Form available at the APS website (https://mc.manuscriptcentral.com/archplastsurg) including each patient's signature.

**Statement of Human and Animal Rights**

Clinical research should be done in accordance with the Ethical Principles for Medical Research Involving Human Subjects, as outlined in the Helsinki Declaration (https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/). Clinical studies that do not meet the Helsinki Declaration will not be considered for publication. For publication, the human subjects' identifiable information, such as the patients' names, initials, hospital numbers, dates of birth, or other protected healthcare information should not be disclosed. For animal subjects, the research should be performed based on the National or Institutional Guide for the Care and Use of Laboratory Animals, and the ethical treatment of all experimental animals should be maintained.

**Authorship and Author's Responsibility**

Authorship credit should be based on (1) substantial contributions to conception and design, acquisition of data, and analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; (3) final approval of the version to be published; and (4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Authors should meet these four conditions.

- A list of each author's role should accompany the submitted paper.

- Correction of authorship: Any requests for such changes in authorship (adding author(s), removing author(s), or rearranging the order of authors) after the initial manuscript submission and before publication should be explained in writing to the editor in a letter or e-mail from all authors. This letter must be signed by all authors of the paper. A copyright assignment must be completed by every author.

- Role of corresponding author: The corresponding author takes primary responsibility for communication with the journal during the manuscript submission, peer review, and publication process. The corresponding author typically ensures that all of the journal's administrative requirements, such as providing the details of authorship, ethics committee approval, clinical trial registration documentation, and conflict of interest forms and statements, are properly completed, although these duties may be delegated to one or more coauthors. The corresponding author should be available throughout the submission and peer review process to respond to editorial queries in a timely manner, and after publication, should be available to respond to critiques of the work and cooperate with any requests from the journal for data or additional information or questions about the article.

- Contributors: Any researcher who does not meet all four ICMJE criteria for authorship discussed above but contribute substantively to the study in terms of idea development, manuscript writing, conducting research, data analysis, and financial support should have their contributions listed in the Acknowledgments section of the article.
Originality and Duplicate Publication

Submitted manuscripts must represent original research not previously published nor being considered for publication elsewhere. The editors and Thieme combat plagiarism, double publication, and scientific misconduct with the software CrossCheck powered by iThenticate. Your manuscript may be subject to an investigation and retraction if plagiarism is suspected. If you plan to reproduce text, tables, or figures from a published source, you must first obtain written permission from the copyright holder (usually the publisher). This is required even if the material is from your own published work. For material never before published and given to you by another person, you must obtain permission from that person. Serious delays to publication can be incurred if permissions are not obtained. As the author, it is your responsibility to obtain all permissions, pay any permission fees, furnish copies of permissions to Thieme with your manuscript, and include a credit line at the end of the figure caption, beneath the table, or in a text footnote.

Secondary Publication

It is possible to republish manuscripts if the manuscripts satisfy the conditions of secondary publication of the ICMJE Recommendations.

Process for Managing Research and Publication Misconduct

When the journal faces suspected cases of research and publication misconduct, such as redundant (duplicate) publication, plagiarism, fraudulent or fabricated data, changes in authorship, undisclosed conflict of interest, ethical problems with a submitted manuscript, appropriation by a reviewer of an author's idea or data, and complaints against editors, the resolution process will follow the flowchart provided by COPE (http://publicationethics.org/resources/flowcharts). The discussion and decision on the suspected cases are carried out by the Editorial Board.

Editorial Responsibilities

The Editorial Board will continuously work to monitor and safeguard publication ethics: guidelines for retracting articles; maintenance of the integrity of academic records; preclusion of business needs from compromising intellectual and ethical standards; publishing corrections, clarifications, retractions, and apologies when needed; and excluding plagiarized and fraudulent data. The editors maintain the following responsibilities: responsibility and authority to reject and accept articles; avoid any conflict of interest with respect to articles they reject or accept; promote the publication of corrections or retractions when errors are found; and preserve the anonymity of reviewers.

PEER REVIEW PROCESS

All manuscripts will be evaluated by three peer reviewers who are selected by the editors. The acceptance criteria for all papers are based on the quality and originality of the research and its clinical and scientific significance. An initial decision will normally be made within 3 weeks after the agreement of review by the reviewers, and the reviewers' comments will then be sent to the corresponding authors.

Revised manuscripts must be submitted online by the corresponding author. The corresponding author must indicate the alterations that have been made in response to the referees' comments item by item in a response note and the submitted original file with tracing. Failure to resubmit the revised manuscript within 8 weeks of the editorial decision is regarded as a withdrawal. The editorial office should be notified if additional time is needed or if an author chooses not to submit a revision. The editorial committee makes decisions concerning editing, revision, and acceptance or rejection, and editing may include shortening an article, reducing the number of illustrations or tables, or changing the paper's format or the order of the manuscript. Authors can track the progress of a manuscript on the journal's peer review system.
COPYRIGHTS, DATA SHARING, AND ARCHIVING

Copyright and Open Access Policy

All contributions accepted and published in Archives of Plastic Surgery are fully Open Access meaning that all contributions are immediately made freely available to read, download, and share under the terms of a CC BY License (Creative Commons - Attribution 4.0 International - CC BY 4.0). This license means that anyone may freely use, adapt, redistribute, and reproduce the material in any medium or format, even commercially, provided that the Contributor(s) and the Contribution as the source are acknowledged, a link to the Open Access License is provided and any modifications of the material are indicated.

Data Sharing

Reproducibility of scientific research is at the heart of the scientific enterprise. Hence, we promote transparency and openness of research data. Authors should keep accurate records of their data that are needed to help others understand, check, and reproduce new discoveries. APS encourages data sharing wherever possible, unless this is prevented by ethical, privacy, or confidentiality matters. Authors wishing to do so may deposit their data in a publicly accessible repository and include a link to the DOI within the text of the manuscript. For further information, please refer to the Thieme Data Sharing Policy.

Archiving Policy

Thieme journals encourage the submission of papers that have been deposited in an initial draft version in preprint repositories such as ChemRxiv, arXiv, bioRxiv, Research Square, arXiv, and medRxiv. When posting to a preprint server, authors should retain copyright on their publication. Drafts of short conference abstracts or degree theses posted on the website of the degree-granting institution, and draft manuscripts deposited on authors’ or institutional websites are also welcome. All other prior publication is not acceptable.

During submission, authors should (1) note use of the preprint repository in the cover letter, (2) state what adjustments and/or updates the draft has undergone between deposition and submission and (3) cite the preprint, including the DOI, as a reference in the manuscript.

The submitted manuscript (which is under review for publication in a journal) may be deposited on a preprint server at any time. Upon publication authors should add a link from the preprint to the published article.

In subscription and hybrid open access journals, the preprint version may be updated with the author accepted manuscript (AAM) twelve months after publication. The author accepted manuscript (AAM) is the version that has been accepted for publication. It usually includes revisions resulting from peer review but will be further modified by copyediting and typesetting before final publication. For further information, please refer to the Thieme Journal Policies.

International Sanctions

May 2023

Thieme is obliged to comply with international sanctions imposed amongst others by the EU, USA, UK, and Australia, which sanction certain territories, persons, and entities. For further information, please refer to the Guidelines regarding International Sanctions Affecting Submitted Papers.

Artificial Intelligence and Authorship

Thieme aligns itself with the COPE Position Statement on Artificial Intelligence (AI) and Authorship.
ARTICLE PROCESSING CHARGES

All submissions accepted and published in Archives of Plastic Surgery are fully Open Access, meaning that all contributions are immediately made freely available to read, download, and share under the terms of a CC License. Upon acceptance of your manuscript, the payment of the article processing charge (APC) is due. An article will be moved into production once payment has been received. Learn more about Thieme’s Open Access program by visiting Open Access - Journal authors - Thieme Group. For the current pricing, please go to “APC” and select “Price List”.

MANUSCRIPT PREPARATION

Publication Type
APS publishes editorial, review articles, original articles, case reports, ideas and innovations, continuing medical education, book reviews, letters and communications.

1. Editorials are invited perspectives on an area of plastic surgery, dealing with very active fields of research, current surgical interests, fresh insights, and debates.
2. Review articles provide a concise review of a subject of importance to plastic surgery researchers written by an invited expert in plastic surgery.
3. Original articles are papers reporting the results of basic and clinical investigations that are sufficiently well documented to be acceptable to critical readers.
4. Case reports/ideas and innovations deal with clinical cases of surgical interest or innovation.
5. Continuing medical education describes the recent approaches and developments of plastic and reconstructive surgery for practitioners or trainees.
6. Book reviews may be published when receiving new books to be introduced to plastic and reconstructive surgeons. Authors or publishing companies are welcomed to submit their recent published books to the editorial office.
7. Letters are short original research articles on issues important to researchers.
8. Brief notes are short reports on a case or surgical tips.
9. Communications are interesting and instructive information for readers.

<table>
<thead>
<tr>
<th>Publication type</th>
<th>Abstract/summary</th>
<th>Main text</th>
<th>Reference</th>
<th>Fig. + Table</th>
<th>Supplemental data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original article</td>
<td>250 words</td>
<td>3000 words</td>
<td>40</td>
<td>20</td>
<td>10</td>
</tr>
<tr>
<td>Special topic</td>
<td>250 words</td>
<td>4000 words</td>
<td>No limit</td>
<td>30</td>
<td>10</td>
</tr>
<tr>
<td>Review</td>
<td>200 words</td>
<td>4000 words</td>
<td>No limit</td>
<td>30</td>
<td>10</td>
</tr>
<tr>
<td>Case report</td>
<td>150 words</td>
<td>1500 words</td>
<td>20</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Idea &amp; Innovation</td>
<td>250 words</td>
<td>1500 words</td>
<td>20</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Communication &amp; Letter</td>
<td>No abstract</td>
<td>800 words</td>
<td>10</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

General Guidelines

1. The main document with the manuscript text and tables should be prepared with in an MS Word or RTF format in English. Manuscripts may be rejected due to poor language. Authors can procure English service edit services at Medical & Scientific Paper Editing For Thieme Authors & Members | Enago. Thieme authors receive a 20% discount.
2. The manuscript should be written in 10-point font with double line spacing on A4 sized (21.0 × 29.7 cm) paper with 2.5 cm margins on the top, bottom, right, and left.
3. There should be no mention of the institution where the work was carried out, especially in the Abstract and Methods section. If the institution should be inserted, include it after acceptance of an article.
4. The use of acronyms and abbreviations is discouraged and should be kept to a minimum. When used, they are to be defined where first used, followed by the acronym or abbreviation in parentheses.
5. Drug and chemical names should be stated in standard chemical or generic nomenclature.
6. Units of measure should be presented according to the International System (SI) of Units. All units must be preceded by one space except percentage (%) and temperature (°C).
7. Descriptions of genes or related structures in a manuscript should include the names and official symbols provided by the US National Center for Biotechnology Information (NCBI) or the HUGO Gene Nomenclature Committee.

8. Statistical expression: mean and standard deviation should be described as mean ± SD, and mean and standard error as mean ± SE. P-values should be described as P < 0.05 or P = 0.003.

9. Generic and brand name of medicine: for medicine, use generic names. If a brand name should be used, insert it in parentheses after the generic name.

10. Ensure correct use of the terms sex (when reporting biological factors) and gender (identity, psychosocial or cultural factors), and, unless inappropriate, report the sex and/or gender of study participants, the sex of animals or cells, and describe the methods used to determine sex and gender. If the study was done involving an exclusive population, for example in only one sex, authors should justify why, except in obvious cases (e.g., prostate cancer). Authors should define how they determined race or ethnicity and justify their relevance.

**Reporting Guidelines for Specific Study Designs**

For specific study designs, such as randomized control studies, studies of diagnostic accuracy, meta-analyses, observational studies, and non-randomized studies, authors are encouraged to consult the reporting guidelines relevant to their specific research design. A good source of reporting guidelines is the EQUATOR Network (https://www.equator-network.org) and NLM (https://www.nlm.nih.gov/services/research_report_guide.html).

**ORIGINAL ARTICLES**

Manuscripts will not be acceptable for publication unless they meet the following editorial requirements. Manuscripts must include (1) Title page, (2) Structured abstract and Key words, (3) Main text (Introduction, Methods, Results, Discussion), (4) Conflict of interest, (5) References, (6) Tables, (7) Figure legends, and (8) Supplemental data. Each component should begin on a new page in the following sequence. The main text should be limited to 3000 words, not including the abstract, references, tables, or figures. Original articles may include up to 20 figures and tables combined, 40 references, and 10 supplemental data items.

**1) Title Page**

A running title (no more than 40 characters in length), manuscript title, and each author's full name (include ORCID) and affiliation including the name of the country, should be provided. For a multicenter study, indicate each individual's affiliation using a superscript Arabic number (1, 2, 3…). All persons designated as authors should be qualified for authorship. Each author should have participated sufficiently in the work to take public responsibility for the content. A 'corresponding author' for reprints should be indicated, and full contact information (including address, telephone number, fax number, and e-mail) should be provided. The contributions of all authors must be described using the CRediT (https://www.casrai.org/credit.html) Taxonomy of author roles. All persons who have made substantial contributions, but who have not met the criteria for authorship (e.g., “scientific adviser,” “data collection,” or “participation in clinical trial”), are acknowledged here. Any financial disclosure or support (grant number, institution, and location), thesis article (title and reviewers' page), and presentation history (name of the meeting and date) at a meeting should be included if relevant.

**2) Abstract and Keywords**

The abstract should include the following sections in the specified order: Background, Methods, Results, and Conclusions. It should be no longer than 250 words. Following the abstract, provide 3 to 5 keywords, with each keyword beginning with a capital letter (e.g., Surgery, Plastic / Mammaplasty / Free Tissue Flaps).

**3) Main Text**

**Introduction**: The purpose of the investigation, including relevant background information, should be briefly described.

**Methods**: The research plan, the materials (or subjects), and the methods used should be described, in that order. How the disease was confirmed and how subjectivity in observations was controlled should be explained in detail. When the experimental methodology is the main issue of the paper, the process should be described in detail so as to recreate the experiment as closely as possible. The sources of the apparatus or reagents used should be given along with the source location (name of company, city, and country). If relevant, information on the IRB/IACUC approval and informed consent should be included. Methods of statistical analysis and criteria for statistical significance should be described.
**Results:** The results should be presented in logical sequence in the text, tables, and illustrations. The text should not repeat all the data in the tables or figures but describe important points and trends.

**Discussion:** Observations pertaining to the results of research and other related materials should be interpreted for your readers. New and important observations should be emphasized; the contents in the Introduction or Results should not be simply repeated. The meaning of the observed opinion, along with its limits, should be explained, and within the limits of the research results, the conclusion should be connected to the purpose of the research.

(4) **Conflict of Interest**

The corresponding author of an article is asked to inform the editor of the authors’ potential conflicts of interest possibly influencing their interpretation of data. A potential conflict of interest should be disclosed in the manuscript even when the authors are confident that their judgments have not been influenced in preparing the manuscript. Such conflicts may be financial support or private connections to pharmaceutical companies, political pressure from interest groups, or academic problems (e.g., employment/affiliation, grants or funding, consultancies, stockownership or options, royalties, or patents filed, received, or pending).

(5) **References**

References should be directly relevant to the content of the submitted paper and should not exceed 40 in number. References should be numbered consecutively in the order in which they are first mentioned in the text. Each reference should be cited as [1], [1,4], or [1-3], at the end of the related sentence in the text. The abbreviated journal title should be used according to the NLM Catalog: Journals referenced in the NCBI Databases ([http://www.ncbi.nlm.nih.gov/ncbdatabases/journals](http://www.ncbi.nlm.nih.gov/ncbdatabases/journals)) and the List of KoreaMed Journal Information ([https://journals.koreamed.org/](https://journals.koreamed.org/)). If there are three or fewer authors in a reference, then all the names of the authors should be listed. If the number of authors is greater than three, list the initial three authors, and then abbreviate the rest of the authors with ‘et al.’.

Unpublished observations and personal communication should not be used as references, although references to written, not oral communication may be inserted (in parentheses) in the text. Abstracts published in a citable journal may be cited. To cite a paper accepted but not yet published, state the paper’s DOI number. References must be verified by the author(s) against the original documents. Other types of references not described below should follow Citing Medicine: The NLM style guide for authors, editors, and publishers ([http://www.ncbi.nlm.nih.gov/books/NBK7256/](http://www.ncbi.nlm.nih.gov/books/NBK7256/)).

**Sample references are given below:**

**Journal Article**

3. Books

**Website**

(6) Tables
Tables should be typed double-spaced on separate pages within manuscript, and they should be titled and numbered in Arabic numerals in the order of their first citation in the text. Each column should be given a short heading. Only the first letter of the first word in each row and column should be capital letters. If numerical measurements are given, the unit of measurement should be included in the column heading. The statistical significance of observed differences in the data should be indicated by the appropriate statistical analysis. All nonstandard abbreviations should be defined in footnotes. For special remarks, lower case letters in superscripts a), b), c), d), e)…. should be used.

Table 1. Treatment modality

<table>
<thead>
<tr>
<th>Variable</th>
<th>TRAM-LR group</th>
<th>MRM-LR group</th>
<th>Total</th>
<th>P-value a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wide excision</td>
<td>4 (22.20)</td>
<td>7 (18.40)</td>
<td>11 (19.60)</td>
<td>0.73</td>
</tr>
<tr>
<td>Wide excision + RT</td>
<td>12 (6.0)</td>
<td>24 (63.2)</td>
<td>36 (64.3)</td>
<td>0.79</td>
</tr>
<tr>
<td>Wide excision + skin graft</td>
<td>1 (5.6)</td>
<td>4 (10.5)</td>
<td>5 (8.9)</td>
<td>1.0</td>
</tr>
<tr>
<td>RT</td>
<td>1 (5.6)</td>
<td>3 (7.9)</td>
<td>4 (7.2)</td>
<td>1.0</td>
</tr>
</tbody>
</table>

Values are presented as number (%).
TRAM, transverse rectus abdominis myocutaneous; LR, local recurrence; MRM, modified radical mastectomy; RT, radiotherapy.
a) Chi-square test.

(7) Figures
Each figure should be submitted in a separate file, at a resolution of more than 300 dpi. Lettering and identifying marks should be clear, and the type size should be consistent on each figure. Capital letters should be used for specific areas of identification in a figure. Symbols, lettering, and numbering should be distinctly recognizable so that when the figure is reduced for publication each item will still be legible. Short titles and detailed explanations belong in the figure legends, not on the illustrations themselves. Figure legends should not be included in the same file as the figure but placed instead on a page at the end of the manuscript. The figures should be numbered in the form Fig. 1, Fig. 2, and Fig. 3. Only the first letter of the first word in the title and data should be capital letters. Related figures should be combined into one figure, with each subfigure denoted by the letters, A, B, C, and so on, following the Arabic number of the main figure (e.g., Fig. 1A, Fig. 1B, C). Do not label in the corner using capital letters on each figure. The illustrations of pathological tissue should state clearly the type of stain (e.g., H&E, × 400), and the main contents should be marked by signs or arrows on the picture. The Editorial Committee may request that hand drawn illustrations be redrawn by a graphic designer.

(8) Supplemental Data
Additional data, including methods, results, references, tables, figures, and videos, that are difficult to be inserted in the main body can be submitted in the form of supplemental data. Supplemental data submitted by the author will be published online together with the main body without going through a separate editing procedure. All supplemental data, except video materials, are to be submitted in a single file, and the manuscript title, authors’ title, organization, and corresponding author’s contact information must be specified in the first page.
EDITORIAL

Editorials are invited by the editor and should be commentaries on articles published recently in the APS. Editorial topics could include active areas of research, fresh insights, and debates in all fields of plastic and reconstructive surgery. Editorials should not exceed 2,000 words, excluding references, tables, and figures.

REVIEW ARTICLES / TOPIC

Review and Topic papers will be requested by the editors. They are generally prepared in the same format as original articles, but the details of the manuscript format may be flexible according to its content. Manuscripts are limited to 4,000 words and should include a 250-word summary instead of an unstructured abstract. Review articles present an up-to-date summary of extant knowledge of a given topic. For this reason, review articles—also sometimes known as survey articles—do not report new findings or propose novel analyses, but instead present an overview of studies that have been previously published on a given topic and may conclude by pointing out promising areas for further research.

CASE REPORT

Case reports should be unique, that is, never reported or similar to previously reported cases but with unique characteristics related to location, presenting different symptoms, or using a new diagnosis or management modality. They should include an abstract, introduction, case(s), discussion, references, tables, and figures legend in that order. The case report should be limited to 1,500 words of main text and include no more than 10 sheets of figures and tables, 20 references, and 10 supplemental data items. The abstract should be unstructured and not exceed 150 words.

IDEAS AND INNOVATIONS

Ideas and innovations should be unique, that is, never reported or similar to previously published ideas and innovations. They should include an abstract, introduction, idea(s), discussion, references, tables, and figures legend in that order. The idea innovation submission should be limited to 1,500 words of main text, with up to 10 sheets of figures and tables, 20 references, and 10 supplemental data items. The abstract should be unstructured and no longer than 250 words.

LETTERS

This section of the journal is set aside for critical comments directed to a specific article that has recently been published in the journal. Letters should be concise, no more than 800 words, double-spaced, and include a maximum of 10 citations. Figures and tables should be limited to 2 sheets. The letters and replies should be prepared according to journal format. Illustrative material can be accepted only with the permission of the editor. The authors should include a complete mailing address, telephone and fax numbers, and e-mail address with their correspondence. The title of your letter should be identical to the title of the published article being discussed. The editor reserves the right to shorten letters, delete objectionable comments, and make other changes to comply with the style of the journal.

COMMUNICATIONS

The article type Communications is intended for sharing practical concerns or topics of particular interest to APS readers. Unlike Original Articles, Communications do not need to follow the formal journal article structure. Authors are encouraged to present their ideas in an unstructured format for greater readability and ease of understanding. Therefore, please avoid dividing the content into sections such as Introduction, Methodology, Results, Discussion, and Conclusion. The communication should be limited to 800 words of main text, include up to 2 sheets of figures and tables, 10 references, and 2 supplemental data items.
**FINAL PREPARATION FOR PUBLICATION**

**Final Version**

Please upload a clean version with your revision. This version will be used for you AAM publication once the article is accepted.

The names and affiliations of the authors should be double-checked, and if the originally submitted image files were of poor resolution, higher resolution image files should be submitted at this time. Symbols (e.g., circles, triangles, squares), letters (e.g., words, abbreviations), and numbers should be large enough to be legible on reduction to the journal's column widths. All symbols must be defined in the figure caption. If references, tables, or figures are moved, added, or deleted during the revision process, renumber them to reflect such changes so that all tables, references, and figures are cited in numeric order.

All figures and tables should be provided in separate files and cited in the main document.

**Galley Proof**

The author(s) will receive the final version of the manuscript as a PDF file. Upon receipt, the author(s) must notify the editorial office (or printing office) of any errors found in the file within 48 hours. Any errors found after this time are the responsibility of the author(s) and will have to be corrected as an erratum.

**Errata and Corrigenda**

To correct errors in published articles, the corresponding author should contact the journal's Editorial Office with a detailed description of the proposed correction. Corrections that profoundly affect the interpretation or conclusions of the article will be reviewed by the editors. Corrections will be published as corrigenda (corrections of the author's errors) or errata (corrections of the publisher's errors) in a later issue of the journal.